Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

Launched by CHONG KUN DANG PHARMACEUTICAL · Oct 14, 2024

Keywords

ClinConnect Summary

This clinical trial is designed to test a medication called CKD-202A, which is a combination of two drugs, Sacubitril and Valsartan, to see how well it works and how safe it is for people with essential hypertension, also known as high blood pressure. The trial is currently not recruiting participants, but it will include adults aged 19 and older who choose to join and sign the necessary consent forms.

To be eligible, participants should not have certain health issues, like specific types of high blood pressure or poorly controlled diabetes. They should also not be pregnant or breastfeeding, and they need to agree to use birth control during the trial. Participants can expect to receive the study medication and will be monitored by healthcare professionals throughout the trial. This is an important step in finding new treatments for high blood pressure, which affects many people and can lead to serious health problems if not managed properly.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who are 19 years old or older.
• • Participants who have voluntarily decided to participate in this clinical trial and signed ICF.
• Exclusion Criteria:
• • Participants with a history of secondary hypertension or suspected secondary hypertension.
• • Participants with a orthostatic hypotension.
• • Participants who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period.
• • Participants with type 1 diabetes or poorly controlled diabetes.
• • Participants who treated other clinical trial drugs within 4 weeks of screening visit.
• • Participants with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening
• • Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug
• • Participants who are unable to participate in this clinical trial at the discretion of the investigator.